Bone remodeling is a critical physiological process that maintains skeletal health by balancing bone resorption (osteoclast activity) and bone formation (osteoblast activity). Disorders of bone remodeling, or metabolic bone diseases, include osteoporosis, renal osteodystrophy, osteopetrosis, Paget's disease, and rickets. These conditions arise from imbalances in bone remodeling, often due to hormonal changes, aging, drug use, or secondary diseases. Osteoporosis, the most prevalent, is characterized by low bone mass and increased fracture risk, with two main types: postmenopausal (linked to estrogen deficiency) and age-related. Secondary osteoporosis results from other conditions or treatments. Renal osteodystrophy, associated with chronic kidney disease, involves abnormal bone mineralization and PTH regulation. Osteopetrosis is a rare condition with impaired bone resorption, leading to increased bone density. Paget's disease is a focal disorder of high bone turnover, causing abnormal bone structure and increased osteosarcoma risk. Rickets, a childhood disorder, results from vitamin D deficiency. Bone remodeling involves the basic multicellular unit (BMU), with osteocytes playing a key role in sensing mechanical stress. The RANKL/RANK/OPG system regulates osteoclast activity, and estrogen deficiency contributes to postmenopausal osteoporosis. Treatments include bisphosphonates, PTH analogs, and calcium/vitamin D supplements. Immobilization-induced osteoporosis results from reduced mechanical stress. Understanding these mechanisms is crucial for developing effective therapies for metabolic bone diseases.Bone remodeling is a critical physiological process that maintains skeletal health by balancing bone resorption (osteoclast activity) and bone formation (osteoblast activity). Disorders of bone remodeling, or metabolic bone diseases, include osteoporosis, renal osteodystrophy, osteopetrosis, Paget's disease, and rickets. These conditions arise from imbalances in bone remodeling, often due to hormonal changes, aging, drug use, or secondary diseases. Osteoporosis, the most prevalent, is characterized by low bone mass and increased fracture risk, with two main types: postmenopausal (linked to estrogen deficiency) and age-related. Secondary osteoporosis results from other conditions or treatments. Renal osteodystrophy, associated with chronic kidney disease, involves abnormal bone mineralization and PTH regulation. Osteopetrosis is a rare condition with impaired bone resorption, leading to increased bone density. Paget's disease is a focal disorder of high bone turnover, causing abnormal bone structure and increased osteosarcoma risk. Rickets, a childhood disorder, results from vitamin D deficiency. Bone remodeling involves the basic multicellular unit (BMU), with osteocytes playing a key role in sensing mechanical stress. The RANKL/RANK/OPG system regulates osteoclast activity, and estrogen deficiency contributes to postmenopausal osteoporosis. Treatments include bisphosphonates, PTH analogs, and calcium/vitamin D supplements. Immobilization-induced osteoporosis results from reduced mechanical stress. Understanding these mechanisms is crucial for developing effective therapies for metabolic bone diseases.